ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $171,119 | -39.3% | 77,081 | -26.7% | 0.00% | – |
| Q1 2024 | $281,859 | -65.9% | 105,171 | -62.0% | 0.00% | – |
| Q4 2023 | $827,770 | +233.8% | 276,846 | +9.4% | 0.00% | – |
| Q3 2023 | $248,000 | -25.8% | 253,061 | +5.2% | 0.00% | – |
| Q2 2023 | $334,269 | +14.2% | 240,481 | +30.6% | 0.00% | – |
| Q1 2023 | $292,694 | -50.5% | 184,084 | +93.8% | 0.00% | – |
| Q4 2022 | $591,685 | +975.8% | 94,974 | +1042.3% | 0.00% | – |
| Q3 2022 | $55,000 | 0.0% | 8,314 | -4.1% | 0.00% | – |
| Q2 2022 | $55,000 | +77.4% | 8,669 | +30.0% | 0.00% | – |
| Q1 2022 | $31,000 | -99.1% | 6,666 | -94.8% | 0.00% | – |
| Q4 2020 | $3,307,000 | -30.1% | 127,199 | -0.0% | 0.00% | – |
| Q3 2020 | $4,728,000 | -33.4% | 127,200 | -8.1% | 0.00% | -100.0% |
| Q2 2020 | $7,103,000 | +8.6% | 138,440 | -33.3% | 0.00% | 0.0% |
| Q1 2020 | $6,543,000 | -46.7% | 207,529 | +0.8% | 0.00% | 0.0% |
| Q4 2019 | $12,275,000 | +50.7% | 205,864 | -7.4% | 0.00% | 0.0% |
| Q3 2019 | $8,148,000 | -35.8% | 222,253 | -18.5% | 0.00% | 0.0% |
| Q2 2019 | $12,682,000 | -45.5% | 272,629 | -52.9% | 0.00% | -66.7% |
| Q1 2019 | $23,256,000 | -31.6% | 579,236 | -21.6% | 0.00% | -40.0% |
| Q4 2018 | $34,007,000 | +49.1% | 739,289 | +43.8% | 0.01% | +66.7% |
| Q3 2018 | $22,810,000 | -36.9% | 514,084 | -44.3% | 0.00% | -25.0% |
| Q2 2018 | $36,172,000 | -71.0% | 922,979 | -46.5% | 0.00% | -73.3% |
| Q1 2018 | $124,781,000 | +51.0% | 1,725,169 | +37.5% | 0.02% | +50.0% |
| Q4 2017 | $82,628,000 | +22.8% | 1,254,988 | -6.5% | 0.01% | +25.0% |
| Q3 2017 | $67,306,000 | +8.6% | 1,342,888 | +0.3% | 0.01% | 0.0% |
| Q2 2017 | $61,950,000 | +34.1% | 1,338,588 | +2.3% | 0.01% | +33.3% |
| Q1 2017 | $46,206,000 | +381.8% | 1,308,588 | +70.8% | 0.01% | +500.0% |
| Q4 2016 | $9,590,000 | -9.6% | 766,009 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $10,609,000 | +0.5% | 766,009 | -28.3% | 0.00% | 0.0% |
| Q2 2016 | $10,561,000 | -46.9% | 1,068,950 | -9.1% | 0.00% | -66.7% |
| Q1 2016 | $19,882,000 | -52.5% | 1,175,750 | -37.5% | 0.00% | -50.0% |
| Q4 2015 | $41,854,000 | -30.0% | 1,880,250 | -25.9% | 0.01% | -33.3% |
| Q3 2015 | $59,831,000 | -66.9% | 2,536,271 | +14.8% | 0.01% | -60.9% |
| Q2 2015 | $180,627,000 | -10.8% | 2,209,232 | +1.0% | 0.02% | -11.5% |
| Q1 2015 | $202,454,000 | +257.3% | 2,186,332 | +56.0% | 0.03% | +271.4% |
| Q4 2014 | $56,668,000 | +2664.3% | 1,401,274 | +1572.2% | 0.01% | – |
| Q3 2014 | $2,050,000 | +54.5% | 83,800 | 0.0% | 0.00% | – |
| Q2 2014 | $1,327,000 | -1.5% | 83,800 | -5.9% | 0.00% | – |
| Q1 2014 | $1,347,000 | +10.0% | 89,100 | 0.0% | 0.00% | – |
| Q4 2013 | $1,224,000 | -86.8% | 89,100 | -81.9% | 0.00% | -100.0% |
| Q3 2013 | $9,298,000 | – | 493,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
| Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
| Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
| RA Capital Management | 704,701 | $24,883,000 | 3.05% |
| Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
| BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
| Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
| Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
| Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
| FT Options LLC | 22,834 | $806,000 | 1.06% |